Netherlands-based Elsevier, publisher of science, technical and health information, has acquired healthcare business intelligence company, Windhover Information.
Windhover provides analysis and commentary on healthcare business strategy, industry deal making, marketplace trends and medical start-ups.
It produces journals such as In Vivo and the RPM Report, a comprehensive database of healthcare industry transactions, and a series of medical device and bio-pharmaceutical partnering and strategy conferences.
The acquisition is part of Elsevier’s e-health strategy to improve patient healthcare and the business of health in the pharmaceutical business intelligence market.
“Adding Windhover’s expert analysis of the pharmaceutical and medical device industries to our existing regulatory and general business news services and database expands both the depth and breadth of Elsevier’s customer offerings. Windhover also provides an exciting platform for new products,” said Brian Nairn, CEO of Elsevier Health Sciences.
Windhover Information will expand Elsevier’s offering of new products and services for pharmaceutical industry professionals by combining innovative technology and industry-leading content to promote faster and better informed planning and management of product portfolios.
With Windhover, Elsevier will field a team of more than 100 journalists in bureaus covering healthcare developments around the world.
“Elsevier is one of the few companies as dedicated to covering the business of healthcare as Windhover is,” said Roger Longman and David Cassack, managing partners and co-founders of Windhover.
“We’re proud to align with The Pink Sheet and other F-D-C Reports products and provide growth opportunities for our staff,” they added.
The acquisition of Windhover is Elsevier’s latest in a series of investments in content, workflow tools and e-health services, adding to its recent acquisition, Eclipsys.
Windhover will operate within Elsevier’s Pharma Business Intelligence Unit, which includes F-D-C Reports and Inteleos, a powerful drug development database. Terms of the acquisition are not being disclosed.